InvestorsHub Logo
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

Re: None

Monday, 11/01/2010 7:39:55 AM

Monday, November 01, 2010 7:39:55 AM

Post# of 4126
CPP-115 demonstrates a major improvement in visual safety compared to vigabatrin.

"Based on the strength of this and the other data found in these safety and efficacy studies, the company considers CPP-115 to be the leading candidate as a next generation treatment for addiction and epilepsy. We expect to initiate the remaining studies necessary to file an IND in the third quarter of next year."

http://finance.yahoo.com/news/Catalyst-Pharmaceutical-pz-1812793254.html?x=0&.v=1
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CPRX News